Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Belgian clinical-stage biotech iTeos Therapeutics (Nasdaq: ITOS) saw its shar leap18.6% to $8.20 today, despite posting ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

iTeos and GSK have decided to terminate the belrestotug development program, which could signal a major setback for the company's research efforts. The decision to terminate all belrestotug ...